Surviving PEA in Roanoke (SPEAR) Study
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.
Also called NCT05283850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 342 participants
- Sponsor
- Carol Bernier
- Registry
-
NCT05283850
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05283850. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-16 (actual); primary completion 2027-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Surviving PEA in Roanoke (SPEAR) Study
- Acronym
- SPEAR
- Condition
- Cardiac Arrest
- Condition
- Pulseless Electrical Activity
- Intervention (Drug)
- High Calcium, Low Sodium (HCLS) Crystalloid Therapy
- Intervention (Drug)
- High Calcium, High Sodium (HCHS) Crystalloid Therapy
- Lead sponsor
- Carol Bernier
- Collaborator
- Virginia Polytechnic Institute and State University
Record details
- Record id
cardio:ct-nct05283850- Content hash
a8d126c2e9b8886cbd42e16dfb63410e998b45ddb26b48f37687dc098ee8f346